Craig H Moskowitz (Craig Moskowitz)

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Hodgkin Lymphoma

Diffuse Large B Cell Lymphoma

Placebo Controlled

Top Venues

Leukemia & lymphoma

Clinical cancer research : an official journal of the American Association for Cancer Research

Blood cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom, Brad S Kahl, Weiyun Z Ai, John Radford, Melham M Solh, Kirit M Ardeshna, Brian T Hess, Matthew A Lunning, Pier Luigi Luigi Zinzani, Anastasios Stathis, Carmello Carlo-Stella, Izidore S Lossos, Paolo F Caimi, Sunwoo Han, Fei Yang, Russ A Kuker, Craig H Moskowitz
PET/CT-biomarkers enable risk stratification of patients with relapsed/refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Francesco Maura, Bachisio Ziccheddu, Jenny Zhaoying Xiang, Bhavneet Bhinder, Joel Rosiene, Federico Abascal, Kylee H Maclachlan, Kenneth Wha Eng, Manik Uppal, Feng He, Wei Zhang, Qi Gao, Venkata D Yellapantula, Vicenta Trujillo-Alonso, Sunita I Park, Matthew J Oberley, Elizabeth Ruckdeschel, Megan S Lim, Gerald B Wertheim, Matthew J Barth, Terzah M Horton, Andriy Derkach, Alexandra Elizabeth Kovach, Christopher J Forlenza, Yanming Zhang, Carl Ola Landgren, Craig H Moskowitz, Ethel Cesarman, Marcin Imielinski, Olivier Elemento, Mikhail Roshal, Lisa Giulino-Roth
Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells. Blood cancer discovery (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)